{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:16:37Z","timestamp":1790079397699,"version":"4.0.1"},"reference-count":22,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ascendis Pharma Endocrinology Division"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin in children with growth hormone deficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible subjects completing a prior Phase 3 lonapegsomatropin parent trial (heiGHt or fliGHt) were invited to participate. All subjects were treated with lonapegsomatropin. Subjects in the United States switched to the TransCon hGH Auto-Injector when available. Endpoints were long-term safety, annualized height velocity, pharmacodynamics [insulin-like growth factor-1 SD score (SDS) values], and patient- and caregiver-reported assessments of convenience and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lonapegsomatropin treatment during enliGHten was associated with continued improvements in height SDS through week 104 in treatment-na\u00efve subjects from the heiGHt trial (\u22122.89 to \u22121.37 for the lonapegsomatropin group; \u22123.0 to \u22121.52 for the daily somatropin group). Height SDS also continued to improve among switch subjects from the fliGHt trial (\u22121.42 at fliGHt baseline to \u22120.69 at week 78). After 104 weeks, the average bone age\/chronological age ratio for each treatment group was 0.8 (0.1), showing only minimal advancement of bone age relative to chronological age with continued lonapegsomatropin treatment among heiGHt subjects. Fewer local tolerability reactions were reported with the TransCon hGH Auto-Injector compared with syringe\/needle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the second year of therapy without excess advancement of bone age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac217","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T03:30:45Z","timestamp":1650079845000},"page":"e2680-e2689","source":"Crossref","is-referenced-by-count":32,"title":["Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results"],"prefix":"10.1210","volume":"107","author":[{"given":"Aristides K","family":"Maniatis","sequence":"first","affiliation":[{"name":"Rocky Mountain Pediatric Endocrinology , Centennial, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J","family":"Casella","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital at Dartmouth-Hitchcock , Lebanon NH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulhas M","family":"Nadgir","sequence":"additional","affiliation":[{"name":"Center of Excellence in Diabetes and Endocrinology , Sacramento, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L","family":"Hofman","sequence":"additional","affiliation":[{"name":"Liggins Institute, University of Auckland , Auckland , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saenger","sequence":"additional","affiliation":[{"name":"NYU Langone Health , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena D","family":"Chertock","sequence":"additional","affiliation":[{"name":"Voronezh State Medical University , Voronezh , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M","family":"Aghajanova","sequence":"additional","affiliation":[{"name":"Yerevan State Medical University , Yerevan , Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Korpal-Szczyrska","sequence":"additional","affiliation":[{"name":"Klinika Pediatrii, Diabetologii i Endokrynologii Uniwersyteckie Centrum Kliniczne , Gdansk , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpis","family":"Vlachopapadopoulou","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital. P. A. Kyriakou , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Malievskiy","sequence":"additional","affiliation":[{"name":"Bashkir State Medical University , Ufa , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Chaychenko","sequence":"additional","affiliation":[{"name":"MHI Regional Child Clinical Hospital, Child Endocrinology Center, Kharkiv National Medical University , Kharkiv , Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cappa","sequence":"additional","affiliation":[{"name":"UOC di Endocrinologia, Ospedale Pediatrico Bambino Ges\u00f9, IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Song","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Mao","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Holse","family":"Mygind","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alden R","family":"Smith","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D","family":"Chessler","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison S","family":"Komirenko","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beckert","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S , Hellerup , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5289","authenticated-orcid":false,"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Ascendis Pharma , Palo Alto, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Thornton","sequence":"additional","affiliation":[{"name":"Cook Children\u2019s Health Care System , Fort Worth, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"issue":"2","key":"2022061616040375900_CIT0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apa.15948","article-title":"The history, physiology and treatment safety of growth hormone","volume":"111","author":"Tidblad","year":"2022","journal-title":"Acta Paediatr."},{"key":"2022061616040375900_CIT0002","doi-asserted-by":"crossref","first-page":"637209","DOI":"10.3389\/fendo.2021.637209","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"12","author":"Yuen","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022061616040375900_CIT0003","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PLoS One."},{"issue":"2","key":"2022061616040375900_CIT0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr Pract."},{"key":"2022061616040375900_CIT0005","volume-title":"SKYTROFA (lonapegsomatropin-tcgd)","year":"2022"},{"issue":"1","key":"2022061616040375900_CIT0006","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022061616040375900_CIT0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: Phase II and Phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022061616040375900_CIT0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40265-021-01663-2","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"2022061616040375900_CIT0009","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","article-title":"Weekly lonapegsomatropin in treatment-na\u00efve children with growth hormone deficiency: the Phase 3 heiGHt trial","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022061616040375900_CIT0010","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2016-3776","article-title":"Randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022061616040375900_CIT0011","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EC-17-0203","article-title":"The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency","volume":"6","author":"Sprog\u00f8e","year":"2017","journal-title":"Endocr Connect."},{"key":"2022061616040375900_CIT0012","article-title":"Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency","author":"Lin","year":"2021","journal-title":"Pediatric Endocrine Society"},{"key":"2022061616040375900_CIT0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes."},{"issue":"2","key":"2022061616040375900_CIT0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1210\/jc.2007-1581","article-title":"Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children","volume":"93","author":"Bakker","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022061616040375900_CIT0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/BF03346352","article-title":"Efficacy and safety of a new ready-to-use recombinant human growth hormone solution","volume":"30","author":"Romer","year":"2007","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"2022061616040375900_CIT0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jcem.87.1.8150","article-title":"Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety","volume":"87","author":"Cohen","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022061616040375900_CIT0017","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000105494","article-title":"Randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency","volume":"68","author":"Peterkova","year":"2007","journal-title":"Horm Res Paediatr."},{"issue":"6","key":"2022061616040375900_CIT0018","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol."},{"key":"2022061616040375900_CIT0019","doi-asserted-by":"crossref","DOI":"10.1515\/JPEM.2002.15.S2.715","article-title":"A long-acting human growth hormone (Nutropin Depot\u00ae): efficacy and safety following two years of treatment in children with growth hormone deficiency","volume":"15","author":"Silverman","year":"2002","journal-title":"J Pediatr Endocrinol Metab."},{"key":"2022061616040375900_CIT0020","first-page":"129","article-title":"Understanding compliance issues for daily self-injectable treatment in ambulatory care settings","volume":"2","author":"Brod","year":"2008","journal-title":"Patient Prefer Adherence."},{"issue":"2","key":"2022061616040375900_CIT0021","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpeds.2004.09.009","article-title":"Sex differences in patients referred for evaluation of poor growth","volume":"146","author":"Grimberg","year":"2005","journal-title":"J Pediatr."},{"issue":"4","key":"2022061616040375900_CIT0022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jpeds.2008.10.041","article-title":"Sex-based prevalence of growth faltering in an urban pediatric population","volume":"154","author":"Grimberg","year":"2009","journal-title":"J Pediatr."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac217\/43710770\/dgac217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/e2680\/44110775\/dgac217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/e2680\/44110775\/dgac217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:12:10Z","timestamp":1655381530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/7\/e2680\/6569189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,16]]},"published-print":{"date-parts":[[2022,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac217","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,16]]}}}